Clinical and genetic features of toxic liver damage in workers of petrochemical enterprises

Introduction. Harmful chemicals are often used in petrochemical production, which causes them to be in the air of the work area. Penetrating into the body of workers, chemical compounds can contribute to disorders of the body's health. The formation of chemically active metabolites during the biotransformation of xenobiotics leads to damage to the abdominal organs and causes changes in peripheral blood parameters, which can be used to search for new diagnostic markers of the effects of harmful factors on health.

The study aims to consider the prognostic possibilities of biochemical and genetic indicators for the early diagnosis of toxic liver damage in workers in the chemical industry.

Materials and methods. The experts conducted a study of the health status of 114 workers of petrochemical enterprises and they found toxic liver damage in 29 workers (cohort 1). The comparison group included 92 employees of enterprises in other industries who are not in contact with industrial chemical risk factors, of which 48 people were found to have non-alcoholic fatty liver disease (cohort 3). Scientists conducted clinical studies of the body in workers using biochemical, instrumental and genetic methods.

Results. A study of the prognostic capabilities of predictors of toxic liver damage demonstrated a good potential for biomarkers: the percentage of "comets" with fragmentation of more than 5% of DNA (cut-off=12.24%, Sen=79.3%, Spe=66.7%, AUC ROC=0.711; p<0.001), the average percentage of DNA in the tail of the "comet" (cut-off=2.95%, Sen=79.3%, Spe=60.5%, AUC ROC=0.727; p<0.001), aspartate aminotransferase (cut-off=25.5 U/L, Sen=86.2%, Spe=48.6%, AUC ROC=0.707; p<0.001), direct bilirubin (cut-off=3.05 mmol/L, Sen=72.4%, Spe=75.7%, AUC ROC=0.752; p<0.001).

Conclusion. The results of the study indicate the high prognostic capabilities of certain genetic biomarkers (the percentage of "comets" with fragmentation of more than 5% of DNA, the average percentage of DNA in the tail of the "comet") to differentiate cases of production-related toxic liver damage from cases of non-alcoholic fatty liver disease in the early stages of pathology formation.

Ethics. The study was carried out in accordance with the fundamental documents of the Russian Federation and the international principles of research ethics (minutes of the meeting of the bioethical commission of the Ufa Scientific Research Institute of Occupational Health and Human Ecology of Rospotrebnadzor No. 01-09 dated 30.09.2024).

Limitations. The results obtained are limited by the number of participants (223 workers) and the capabilities of the research methods used (clinical, sonographic, single-cell agarose gel electrophoresis, statistical, ROC analysis).

Contributions:
Kudoyarov E.R. — research concept and design, data collection and processing, text writing;
Ivanova D.P. — data collection and processing;
Bakirov A.B. — research concept and design, editing;
Kalimullina D.Kh. — editing;
Galiullina D.M. — data collection and processing;
Mironova G.R. — data collection and processing.

Funding. The study had no funding.

Conflict of interests. The authors declare no conflict of interests.

Received: 15.11.2024 / Accepted: 02.12.2024 / Published: 07.02.2025

1. Occupational pathology: national guidelines. Edited by N.F. Izmerov. M.: GEOTAR-Media; 2011 (in Russian).

2. Döring B., Petzinger E. Phase 0 and phase III transport in various organs: combined concept of phases in xenobiotic transport and metabolism. Drug Metab. Rev. 2014; 46: 261–82. https://doi.org/10.3109/03602532.2014.882353

3. Joshi-Barve S., Kirpich I., Cave M.C., Marsano L.S., McClain C.J. Alcoholic, nonalcoholic, and toxicant-associated steatohepatitis: mechanistic similarities and differences. Cell. Mol. Gastroenterol. Hepatol. 2015; 1(4): 356–67. https://doi.org/10.1016/j.jcmgh.2015.05.006

4. Idilman I.S., Ozdeniz I., Karcaaltincaba M. Hepatic steatosis: etiology, patterns, and quantification. Semin. Ultrasound CT MR. 2016; 37(6): 501–10. https://doi.org/10.1053/j.sult.2016.08.003

5. Mezale D., Strumfa I., Vanags A., Mezals M., Fridrihsone I., Strumfs B., et al. Chapter 1. Non-alcoholic steatohepatitis, liver cirrhosis and hepatocellular carcinoma: The molecular pathways. Liver Cirrhosis Update and Current Challenges. London: InTech; 2017. https://doi.org/10.5772/intechopen.68771

6. Caro A.A., Cederbaum A.I. Oxidative stress, toxicology and pharmacology of CYP2E1. Annu. Rev. Pharmacol. Toxicol. 2004; 44(1): 27–42. https://doi.org/10.1146/annurev.pharmtox.44.101802.121704

7. McGillicuddy F.C., de la Llera Moya M., Hinkle C.C., Joshi M.R., Chiquoine E.H., Billheimer J.T., et al. Inflammation impairs reverse cholesterol transport in vivo. Circulation. 2009; 119(8): 1135–45. https://doi.org/10.1161/CIRCULATIONAHA.108.810721

8. Muldasheva N.A., Karimov D.O., Karimova L.K., Beigul N.A., Shapoval I.V. Potential chemical risks for workers' health in petrochemical productions. Meditsina Truda i ekologiya cheloveka. 2024; 2: 32–45 (in Russian).

9. Pérez Fernández T., López Serrano P., Tomás E., Gutiérrez M.L., Lledó J.L., Cacho G. et al. Diagnostic and therapeutic approach to cholestatic liver disease. Rev. Esp. Enferm. Dig. 2004; 96(1): 60–73. https://doi.org/10.4321/s1130-01082004000100008

10. Reshetnyak V.I. Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis. World J. Gastroenterol. 2015; 21(25): 7683–708. https://doi.org/10.3748/wjg.v21.i25.7683

11. Jansen P.L.M., Ghallab A., Vartak N., Reif R., Schaap F.G., Hampe J. et al. The ascending pathophysiology of cholestatic liver disease. Hepatology. 2017; 65(2): 722–38. https://doi.org/10.1002/hep.28965

12. Galimova R.R., Karimova L.K., Muldasheva N.A., Valeeva E.T., Gazizova N.R. The foundation of the prevention of occupational morbidity in workers of petrochemical plants. Gigiena i Sanitariya. 2019; 98(9): 967–71. (in Russian).

13. Mayevskaya M.V., Kotovskaya Yu.V., Ivashkin V.T., Tkacheva O.N., Troshina E.A., Shestakova M.V. et al. The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities. Terapevticheskii arkhiv. 2022; 94(2): 216–53 (in Russian).

14. Occupational pathology: national guidelines. Edited by I.V. Bukhtiyarov. M.: GEOTAR-Media; 2024 (in Russian).

15. Non-alcoholic fatty liver disease. Clinical guidelines. 2022. https://cr.minzdrav.gov.ru/recomend/748_1 (date of access: 15.04.2024) (in Russian).

16. MR 4.2.0014–10 "Evaluation of genotoxic properties by the method of DNA comets in vitro": Methodological recommendations. M.: Federal’nyj centr gigieny i epidemiologii Rospotrebnadzora; 2011. (in Russian).

17. Singh N.P., McCoy M.T., Tice R.R., Schneider E.L. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 1988; 175: 184–191.

18. Collins A.R., Ma A.G., Duthie S.J. The kinetics of repair of oxidative DNA damage (strand breaks and oxidised pyrimidines) in human cells. Mutation Research. 1995; 336(1): 69-77.

19. Don E.S., Tarasov A.V., Epshtein O.I., Tarasov S.A. The biomarkers in medicine: search, choice, study and validation. Russian Clinical Laboratory Diagnostics. 2017; 62(1): 52–9. (in Russian).

20. Grigoryev S.G., Lobzin Yu.V., Skripchenko N.V. The role and place of logistic regression and ROC analysis in solving medical diagnostic task. Jurnal Infektologii. 2016; 8(4): 36–45 (in Russian).

21. Rinella M.E., Neuschwander-Tetri B.A., Siddiqui M.S., Abdelmalek M.F., Caldwell S., Barb D. et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023; 77: 1797–835. https://doi.org/10.1097/HEP.000000000000032

22. European Association for the Study of the Liver (EASL). EASL clinical practice guidelines on management of occupational liver diseases. J. Hepatol. 2019; 71: 1022–37.